

How to Cure Cancer: Unbinding Entrepreneurs in Medicine

Arthur M. Diamond, Jr.

Department of Economics
University of Nebraska Omaha
Omaha, NE 68182-0048

(402) 554-3657

adiamond@unomaha.edu

artdiamond.com

Last revised: January 8, 2018

Abstract

Purpose – Since the 1960s, experts have predicted that we are on the verge of curing cancer. The purpose of the paper is to explore the obstacles to progress, and to propose policies that will lead more quickly to more success.

Design/methodology/approach – To speed future cures, we need to look at the traits, and methods of those innovative medical entrepreneurs who achieved breakthroughs in the past, and learn what institutions and policies enabled, or blocked, their progress.

Findings – Breakthrough innovators tend to be less-credentialed outsiders who ‘see what others do not see,’ often by nimble and persistent pursuit of serendipitous discoveries or slow hunches. For example, Freireich and DeVita were less-credentialed outsiders.

Freireich cured childhood leukemia and DeVita cured Hodgkin’s lymphoma, by pursuing nimble trial-and-error experimentation in their anti-cancer chemotherapy cocktails. Min Chiu Li pursued his slow hunch that his patients would benefit from longer chemotherapy than the mandated NCI protocol allowed. He was fired, but his patients were cured. Today FDA mandated regulatory protocols, often defended as applications of the precautionary principle, greatly restrict innovative medical entrepreneurs, thereby delaying cancer cures and costing lives.

Originality/value – The paper proposes a new approach to medical innovation, allowing cancer researchers to engage in trial-and-error experiments that follow up on serendipitous discoveries and plausible hunches. The result will be more cures and longer lives.

Keywords cancer, cures, serendipity, outsider, regulations, FDA, NCI, precautionary principle, medicine, Farber, Freireich, DeVita

Paper type Conceptual paper

1. Introduction

In 2010, about six hundred thousand Americans, and more than 7 million humans around the world, will die of cancer. In the United States, one in three women and one in two men will develop cancer during their lifetime. A quarter of all American deaths, and about 15 percent of all deaths worldwide, will be attributed to cancer. In some nations, cancer will surpass heart disease to become the most common cause of death. (Mukherjee, 2010, p. xv; italics in original)

Health care and education are two of the areas of the economy that are most important to human well-being, and yet have seen the least institutional changes over the past several decades (Bush and Baker, 2014, pp. 61-62). Obstacles in both areas, restrict innovative entrepreneurship, limiting the pace and scope of innovations. In this paper, I argue that reducing the obstacles to innovative medical entrepreneurship will result in quickening the pace of finding cures for more kinds of cancer. My method is to examine important examples of breakthrough innovations in medicine and ask what sort of people made those innovations, and what sort of conditions enabled or obstructed their innovations.

The stakes are high. Gennaway (2011) discusses what Walt Disney might have achieved at Epcot if he had lived several more years. And what neat new device would Steve Jobs have given us next? We all know someone who has cancer, and we all fear

that it may happen to us. Cancer takes away from us life that we thought we would have, and that we ought to have had.

2. Sources of Breakthrough Innovations

Incremental innovations are important and often occur in large firm, university, or government labs staffed by highly credentialed scientists and engineers (Baumol 2005). But major improvements in the quality and quantity of life depend at least as much on breakthrough innovations as on incremental innovations. Breakthrough innovations are not inevitable and do not automatically increase when governments and firms increase their spending on Research and Development. Rather, the agents of breakthrough innovations are almost always innovative entrepreneurs (Baumol 2005). If we want more breakthrough innovations, including more cures for cancers, we need to better understand how innovative entrepreneurs think and act, and what obstacles prevent them from bringing their innovations to the world.

Breakthrough innovations figuratively fly in the face of received theories and expert opinions (Diamond, 2012). Wilbur and Orville Wright's breakthrough innovation *literally* flew in the face of received theories and expert opinions. The innovative entrepreneurs are usually outsiders—"outside" either because of their ignorance of received theories and expert opinions, or "outside" because their willingness to ignore received theories and expert opinions leaves them shunned by the theorists and experts (e.g., see Wang, Veugelers and Stephan, 2017). At a key early stage of a breakthrough innovation, the innovative entrepreneur sees what others do not see. Sometimes a serendipitous event helps the entrepreneur see what others do not see. Sometimes a

different way of thinking, call it “cognitive diversity,” helps the entrepreneur see what others do not see. And sometimes it is mainly courage that helps the entrepreneur see what others do not see.

Because, at the key early stage, the often-inchoate breakthrough innovation will seem indefensible to all but the innovator, the early stage will usually be self-funded (or funded by family or friends who have blind faith in, or affection for, the innovator). As a result, policies that enable self-funding, such as low individual income tax rates, are crucial for enabling entrepreneurs to achieve breakthrough innovations. High tax rates concentrate funds to be spent according to the judgements of the theorists and experts who advise the government. Low tax rates leave more funds widely distributed among the diverse outsiders who have the potential to achieve breakthrough innovations.

3. Examples of Medical Entrepreneurship

Schumpeter saw the key role of the innovative entrepreneur as being the overcomer of obstacles to innovations, which could come in a variety of forms, and from a variety of sources (Schumpeter, 1950, pp. 132-133). In this section I briefly examine a variety of examples in which major medical advances occurred, to see what obstacles were most binding on the medical innovators. The goal will be to see which obstacles can be reduced, in order to enable medical innovators to bring us innovations more quickly and in greater number.

Since our ultimate goal here is to speed cancer cures, many of the examples will be important cancer advances, as identified in Dr. Siddhartha Mukherjee’s acclaimed, and Pulitzer-Prize-winning *The Emperor of All Maladies*. But a few examples will come

from non-cancer medical advances, that were selected either because of their importance in saving lives (the inoculation example) or in revealing the obstacles faced by medical innovators (the ulcer example). These examples are helpful in learning how to speed cancer cures on the plausible assumption that obstacles that impede one kind of medical innovation will be similar to obstacles that impede other kinds of medical innovation.

Histories of medical innovations in general (Meyers, 2007) and medical innovations in fighting heart disease (Miller, 2000) and cancer (Mukherjee, 2010) in particular, show that the innovators frequently resemble Schumpeterian entrepreneurs. They are outsiders from the mainstream, who have the courage and persistence to continue to pursue their innovations in the face of sustained opposition from powerful incumbent medical institutions. Several examples will be briefly discussed.

At the start of the Boston smallpox epidemic of 1721, it is surprising that it was Cotton Mather, of Salem witch trial fame, who wrote a letter to all of the physicians of Boston, suggesting that they start the practice of inoculating the healthy by exposing them to smallpox matter from the infected. Mather had published a small report in the *Philosophical Transactions* of the Royal Society in London, which at the time was one of the world's most distinguished scientific associations (Coss, 2016). In the same issue as his report had been an article by a Greek physician, of Italian descent, reporting his success at performing smallpox inoculations in Constantinople (Coss, 2016). Mather also discovered that one of his slaves had been successfully inoculated in Africa, which led him to seek, and to find, several other slaves in Boston who had been successfully inoculated in Africa.

Mather sent letters to the physicians of Boston, making his case, and urging that they conduct an inoculation experiment. Mather's task was difficult. The only

university-educated physician in Boston, and the most influential, was William Douglass, who disdained Mather as a minister unqualified to make serious contributions to science (Coss, 2016, p. 77). The physicians also may have doubted the testimony of Boston's slaves who had been inoculated in Africa. And everyone found it far-fetched that the worst effects of smallpox could be avoided by an inoculation that exposed a patient to pus from a recent smallpox patient (Coss, 2016, p. 85). With one exception, the entire medical community of the city rejected Mather's evidence and suggestion.

The exception was a young surgeon named Zabdiel Boylston, whose father had been a physician who had observed the success of some American Indian therapies, and so may have been more open than most to possible cures arising from non-European sources (Coss, 2016). On June 26, 1721, Boylston inoculated his first three patients. Among them was Thomas, his youngest son. Boylston was ridiculed and threatened with bodily harm and possible imprisonment. Mather's house was fire-bombed, though the wick from the bomb fortunately fell out before the bomb could ignite. Boylston proceeded to inoculate those who sought inoculation. All those who started the procedure in good health, and without previous exposure to the smallpox, survived, suffered mild cases of smallpox, and were immune to the current and future epidemics of the disease. The handful of those who died after inoculation from Boylston, either were already in the early stages of natural infection from smallpox, or were already frail or infirm from age or other diseases. It would have been easier for Boylston to have refused inoculation to these patients, since he knew that he, and inoculation, would be blamed for their death. But he allowed the patient to decide what risk was worth taking with their life. Boylston's most vitriolic opponent was Dr. William Douglass, who viewed himself as the only true "physician" in Boston, since he was the only one who at received his

medical training at a European medical school, instead of through a then-more-common apprenticeship. To Douglass, his inferior colleagues were “practitioners,” not “physicians.”

Sidney Farber is credited as a founder of chemotherapy for showing that aminopterin could produce temporary remission in childhood leukemia. His path was difficult. He knew that folic acid had succeeded in allowing patients who lacked key nutrients, to return to normal production of blood. So, he speculated that maybe folic acid could have a similar effect on children with leukemia. Farber obtained synthetic folic acid from his friend, the heavily-accented, nocturnal introvert Yellapragada Subbarao (pronounced SubbaRow), who had skill and experience at synthesizing vitamins. But instead of slowing leukemia, injections of Subbarao’s folic acid accelerated it, and shortened the lives of the injected children, which infuriated Farber’s pediatrician colleagues (Mukherjee, 2010, pp. 29-30).

Facing the fury, Farber did not give up. He speculated that if folic acid accelerated leukemia, maybe a drug that blocked folic acid from the cancer cells, would slow leukemia. Farber returned to his friend Subbarao, who had been denied tenure at Harvard, and asked him if he could synthesize a chemical to block folic acid. Serendipitously, it turned out that some small variations in the process to create folic acid, resulted in “antagonists,” chemicals that could block folic acid. One of these was aminopterin. In the clinical trials of aminopterin, the fury of Farber’s colleagues continued. He had to scrounge clinic space in a back room near the bathrooms, with his staff assigned to back rooms and stairwell shafts (Mukherjee, 2010, pp. 34-35). The incumbent medical cancer establishment banned pediatric interns from assisting in Farber’s unit (Mukherjee, 2010, p. 34). The clinical trials often resulted in remission that

extended the lives of the children by a few months, though the leukemia always returned. Farber had not found a cure, but he had found a proof of concept: chemicals could be effective against cancer (Mukherjee, 2010, p. 36). This eventually would lead to chemotherapies for a wide variety of cancers, therapies that often would significantly extend lives, and sometimes even cure.

Min Chiu Li was fired by the U.S. National Cancer Institute (NCI) for continuing to administer chemotherapy after all tumors of cancer of the placenta had disappeared, but before a key marker (the hCG level) had reached zero (Mukherjee, 2010, pp. 136-138). After several years, the NCI eventually noticed that another marker had also reached zero: the number of Li's patients who suffered relapses of their cancer.

Paul Carbone, correctly believing that chemotherapy could aid in treating breast cancer, was caught in a surreal catch-22 situation. The medical establishment would not let him practice his treatment without first conducting a substantial double-blind study. But at that time breast cancer patients were primarily the patients of surgeons, and very few surgeons were willing to enroll their patients in such a study, perhaps because the likely results of the study would be to reduce the role of surgery in breast cancer treatment (Mukherjee, 2010, pp. 219-220). Such medical turf protection also occurred when Vincent DeVita, then head of the NCI, suggested that based on the evidence, post-operative radiation for breast cancer should be reduced, because it was not improving patient outcomes. A radiologist came up to him complaining that much of the radiologist's practice was post-operative breast cancer radiation, and if that was reduced, she¹ would have to fire one of her radiotherapy technicians (DeVita and DeVita-Raeburn, 2015, pp. 182-183).

Turf protection also occurred when Bernard Fisher wanted to test whether radical

mastectomy actually had better outcomes than more modest lumpectomies. His research was substantially delayed because of the resistance of American surgeons to allowing their patients to participate (Mukherjee, 2010, p. 200). After he finally completed his research, breast cancer surgeons almost succeeded in quashing publication of his article in which he presented evidence that lumpectomies were just as effective as radical mastectomies (DeVita and DeVita-Raeburn, 2015, pp. 1082-183; see also pp. 222-223).

Emil Freireich was so aggressive in fighting cancer that he was threatened with firing, but he proceeded anyway. He said that he wouldn't want to work at a place that wouldn't let him do all he could do to save lives (DeVita and DeVita-Raeburn, 2015, pp. 55-56). Week-by-week his team (that one medical intern affectionately called the "Society of Jabbering Idiots") adjusted the dose and composition of the chemical mixture they were developing to fight childhood leukemia (DeVita and DeVita-Raeburn, 2015, pp. 63-64). Most advances in the treatment of cancer have been in terms of months or a few years of longer life. But their work resulted in a rare instance where a type of cancer can frequently and routinely be cured.

Vincent DeVita was a young member of Emil Freireich's team, who soon went on to use the same approach to develop a cure for the cancer known as Hodgkin's lymphoma. Early in his career, DeVita encountered entrenched medical incumbents at the prestigious Memorial Sloan Kettering hospital. The incumbents blasted DeVita's drug cocktail as ineffective against Hodgkin's lymphoma. When he quizzed them about how they had administered it, they admitted that they had cut back the levels of key ingredients, to reduce the possibility of patient nausea (DeVita and DeVita-Raeburn, 2015, p. 110). DeVita was appalled and angry. He said what should have been obvious: most patients would choose temporary nausea over permanent death (DeVita and DeVita-

Raeburn, 2015, pp. 110-111). And the patients, not the physicians, have the right to make this choice.²

DeVita later tried to make changes in medical institutions to increase the pace of cancer innovation, first as head of the NCI, and eventually as physician in chief of the same Memorial Sloan Kettering where he had been blasted as a young researcher. He left the NCI in part from his frustration at having to fight the bureaucracy and special interests within the government (DeVita and DeVita-Raeburn, 2015, pp. 188-189). But he also experienced frustration in the quasi-governmental, non-profit hospital, where entrenched medical incumbents defended their turf against innovations that would save lives. When he was fired from that position, his boss told the hospital board: “the problem with Vince is that he wants to cure cancer” (DeVita and DeVita-Raeburn, 2015, pp. 227-228).

DeVita offers an extended critique of current medical institutions in the United States. He points out that incentives and regulations strongly constrain physicians to follow established protocols. But the kind of entrepreneurial medical innovation achieved by Freireich and his Society of Jabbering Idiots, was achieved through alert, extended trial and error, and could not have been achieved by following the then-mandated protocols. Freireich had been able to survive long enough to cure leukemia in part through the “umbrella” protection of the administrator Tom Frei, who had the courage and skill to sufficiently protect Freireich from the incumbent interests that wanted to rein him in (DeVita and DeVita-Raeburn, 2015, p. 94).

Today DeVita blames a dominant research methodology that says that research proposals need to be carried out as originally approved, even when (as should and does happen) the research process leads the researcher to conclude that the procedures need to

be modified (DeVita and DeVita-Raeburn, 2015, pp. 196-197). This slows progress and loses lives. He also blames the FDA for restricting cancer researchers' ability to experiment with different drug and dose combinations, in the way that led Freireich and his Society to cure leukemia (DeVita and DeVita-Raeburn, 2015, pp. 8, 192 and 254).³

Other approaches, besides variations of chemotherapy, may turn out to be of equal or greater effectiveness against some cancers. We do not understand cancer well enough to foreclose these approaches. One approach that some have considered promising is Judah Folkman's angiogenesis theory. Folkman's research while serving on a submarine led to his insight on developing drugs to cut off blood vessels to tumors (Cooke, 2001; Kounios and Beeman, 2015, pp. 20 and 135-136; Ashton, 2015, pp. 60-65). For a long time, many of Folkman's papers and grant applications were rejected by the medical establishment. Eventually his angiogenesis theory was recognized as plausible and promising, though DeVita suggests that Folkman was too slow to acknowledge that what worked in mice was not working so well in humans (DeVita and DeVita-Raeburn, 2015, pp. 279-280). And his entrepreneurial perseverance and independence may have contributed to his taking a chance on hiring the under-credentialed Robert Langer, who later established an MIT lab, where he made major advances, including polymers to aid targeted drug delivery (Wilkinson, 2015, pp. 169-170).

Another increasingly promising approach is immunotherapy, where some promising results have been achieved by efforts to harness the body's immune system against cancer. Steven Rosenberg is famous for pursuing this approach. He is blunt in discussing how government regulations have slowed down, and discouraged his progress, especially regulations from the FDA. He was kept from doing the kind of quick, nimble adjustments that Jobs did with the iPhone, and that Freireich's Society of Jabbering Idiots

did to cure childhood leukemia. The need to constantly seek approval from the FDA, took him away from the total immersion that would have best served his medical innovation (Rosenberg and Barr, 1992, p. 288). Entrepreneur Jimbo Wales urges his Wikipedians to “be bold” and Rosenberg says that “defeating cancer requires boldness” (1992, p. 325).

4. Generalizations and Implications for Policy

From prominent cases of medical breakthroughs, I highlight four generalizations, and policy implications that are suggested by these generalizations.

Breakthrough innovators are outsiders. George Gilder observes that most innovative entrepreneurs are not successful credentialed insiders, but are unproven, uncredentialed outsiders (1990, pp. 113-114). Gilder's point is re-affirmed in the history of advances of medicine, where breakthrough medical innovations are frequently achieved by outsiders to the incumbent medical establishment. Examples of outsiders in medical innovation include Zabdiel Boylston, Emil Freireich, Jonas Salk, Barry Marshall, and Vincent DeVita. These outsiders have fewer and less prestigious past credentials, and have less funded and less prestigious current positions. Sometimes they are not even in the incumbent disciplines the experts have assigned to the problem.

These claims can be illustrated by many examples. Emil Freireich had been a street kid (Gladwell, 2013). Vincent DeVita had not attended a prestigious medical school (DeVita and DeVita-Raeburn, 2015). In the cancer realm, there are many other examples (Mukherjee, 2010). Ditto for Jonas Salk, whose first independent lab, where he did most of his research to develop the polio vaccine, was not prestigious (Jacobs, 2015).

John Hill, who documented that tobacco use increases the chances of cancer, was viewed as a “buffoon” by the medical establishment (Mukherjee, 2010, pp. 239-240). Zabdiel Boylston was ridiculed by Dr. William Douglass [sic] for being a "practitioner" instead of a physician, since Boylston had received his medical knowledge through the apprenticeship method rather than by attending a European medical school, as Douglass had (Coss, 2016). Australian Barry Marshall was ridiculed by the medical establishment for pointing out evidence that ulcers were caused by bacteria; the ridicule ceased when he swallowed a vial of the bacteria, and developed an ulcer (Meyers, 2007, pp. 103-113; Klein, 2013, pp. 52-56).

The contributions of outsiders are often prominent, not just for practical therapies, but also for fundamental advances in biological knowledge. One of the most fundamental advances in our genetic understanding was first established by the modest monk Gregor Mendel, publishing in a modest regional publication, and long ignored by the biology establishment (Wagner, 2014). Antoine van Leeuwenhoek who first identified microbes, was a cloth merchant and minor city official, not an academic (Snyder, 2015, p. 1). Galileo was supported by Medici bankers, not by incumbent academics (Westfall, 1985). Craig Venter was viewed as an under-credentialed eccentric, as compared to his government-sponsored rival, the Nobel-Prize-winner James Watson (Shreeve, 2004).

Peter Thiel observes that the most important ingredient for successful entrepreneurship is not intelligence, but courage (Thiel and Masters, 2014, p. 5). Since the medical establishment protects its own turf (Bush and Baker 2014; DeVita and DeVita-Raeburn, 2015; Topol, 2012), the success of the less-credentialed has frequently required persistence and courage.

Implications: we should not give too much power to the prestigiously credentialed gate-keepers. We should not marshal resources in a centrally organized plan.

Breakthrough innovations are often achieved by “seeing what others don’t.”⁴

You might say that it was serendipitous that Robin Warren saw the bacteria that cause ulcers. But it is his co-author Barry Marshall who is perhaps better remembered for the discovery. It was he who drank the cocktail of the bacteria, and developed an ulcer. But if “serendipity” implies the good luck to experience a rare event, then that is not quite right for the ulcer case. The bacteria were there for others to see too, and there are published pre-Warren-and-Marshall photographs where we now can identify them, but they were not “seen” by the photographers (Marshall, 2001). Daniel Kahneman has noted that we see what we expect to see. One example is what he calls “theory-induced blindness” (2011, pp. 277, 280, 286-287, and 290). Gastroenterologists widely believed the theory that bacteria could not survive in the acidic environment of the stomach. So they did not “see” the bacteria in photos of the stomach because their theory blinded them. “Serendipity” involves seeing the unexpected. But it involves more. It involves seeing and remembering and having the resources and courage to stick with it, while others are denying it.

Starting in 1891, William Halsted was a tireless advocate of the theory that cancers could be cured by cutting them out (Mukherjee, 2010, pp. 64-69). When surgery often failed to cure, Halsted and his followers blamed the surgeon, not the surgery theory. As failures continued, Halsted and his followers advocated cutting out more and more adjacent lymph nodes, and then more and more adjacent muscles, which increasingly disfigured and disabled patients, but still too often left them dying from the cancer.

Halsted was intense and well-intentioned (Mukherjee, 2010, pp. 5-6, 64-66, and 218), but his theory that surgery could cure cancer blinded him to the growing evidence that cancer often spreads in ways that surgery could not stop.

When Galileo argued for his views of the heavens with the clerical and academic incumbents of his day, he invited some of them to look through his telescope to see for themselves. Some did not look (Bucciantini et al., 2015, pp. 101-102). What was radical about Galilean science was not the individual assertions about the heavens, but that they were to be judged by one's own eyes rather than by the authority of the credentialed. The Royal Society's motto "Nullius in Verba" embraces this method: belief should be based on evidence, not on the words of authorities (Rosen, 2010, p. 68). Breakthrough medical entrepreneurs are frequently in a similar situation. They have the courage and persistence to look, sometimes in straightforward ways, sometimes in non-mainstream ways.

Implications: opportunities for longer-term projects, and multiple funding sources and self-funding, are desirable. When tax rates are low, medical entrepreneurs can more easily accumulate the wealth that enables them to be a funding source for others, or to self-fund. Another implication is that we should tolerate and maybe even value, cognitive diversity.

Breakthrough innovations often come from nimble trial and error. Outside of medicine, Walter Isaacson's book on *Steve Jobs* documents (2011) the importance of nimble trial and error in the development of his signature innovations such as the iPhone. He frequently would have his team present him with four or five versions of a particular product. He then would evaluate them and pick the best for further development. When he was dying of cancer, he was having trouble breathing and the medical staff tried to put an oxygen mask over his face. He stopped them, gasping that he did not like the design

of the mask. He then went on to gasp that they should bring him four or five versions of the mask, and he would pick the best. In the area of cancer research, Min Chiu Li was fired from the National Cancer Institute because he believed that elevated levels of something called hCG indicated that cancer was still lurking at low levels not evidenced by cancer symptoms. His patients did not suffer relapses of their cancers, and he is now viewed as the first to have shown that chemotherapy can cure cancer. Vincent DeVita feels regret that he once stuck with the protocol even though he had learned that the chemotherapy needed to be applied longer than the protocol allowed. His patient died. Is that good science? Is that how to treat our fellow human beings?

Many advances were *not* made following the mainstream mandatory method of medicine, the double-blind method. We know some truths through methods other than double-blind. We have already seen above, that sometimes doctors committed to an incumbent method may not enroll their patients in a double-blind study that might challenge that method. A *reductio ad absurdum* argument has refuted the belief that all medical knowledge must flow from randomized double-blind experiments: no one has ever conducted a randomized double-blind experiment to test the efficacy of parachutes. So, until such an experiment is done, we cannot know that we should wear a parachute when jumping out of an airplane (Smith and Pell, 2003)?

Implication: we should not fund or regulate on the basis of rigid adherence to pre-established protocols, and we should not declare a centrally-planned “war on cancer” or a centrally-planned “cancer moonshot.”

Breakthrough innovations are often achieved at great risk, sometimes even of injury and death. A few died from Boylston’s smallpox inoculations, and even from the

later and safer smallpox vaccinations. But many more lives were saved than lost. And, at least with the inoculation cases, the risks mainly were taken voluntarily.

A growing obstacle to medical innovation has been the growing advocacy and implementation of the “precautionary principle,” which states that new innovations should not be allowed to proceed until it has been shown that they cause no harm (Sunstein 2005; Thierer 2016, p. 1). Perhaps one reason that medical advances have sometimes arisen in war theaters or emergency medicine, is that the precautionary principle is *not* implemented in those settings. For instance, Nobel-Prize winner Alexis Carrel honed his technique for re-attaching small blood vessels in the crucible of WWI⁵ (Friedman, 2007). Examples of medical innovations that were developed under emergency or extreme conditions can be found in Fong (2014).

Such cases show that exemption from the precautionary principle allows for quick and substantial experimental trial-and-error that can speed innovation. They do not provide a justification for war, but they do suggest the pursuit of other ways to counter the precautionary principle. These might include patients voluntarily signing waivers to accept experimental treatments, either because they know that no other treatment is available to them, or because they have made a conscious decision to accept risk for the goal of advancing medicine (DeVita and DeVita-Raeburn, 2015). If we allow extreme athletes to accept risks for the sake of “flow” or the adrenaline rush (Kotler, 2014), should we not also allow thoughtful patients to accept risks for the sake of advancing medical knowledge?

Implication: we must reject the precautionary principle that is increasingly cited to justify the regulation of innovations.

5. How to Cure Cancer

President Richard Nixon predicted in the 1960s that cancer could be eliminated within a generation. He and others declared a "war" on cancer. In the United States after World War II, science and technology policy were heavily influenced by Vannevar Bush, who believed that science and technology should be funded by the government, but that decisions on what research to pursue should be left mainly to academics. Among those who wanted the government to more actively central plan was Mary Lasker, who thought that since the government had succeeded in the centrally planned Manhattan Project, it could also succeed with central planning in other areas, such as in a war on cancer (Mukherjee, 2010, pp. 118-121). Lasker and Bush were each partly right and partly wrong. Lasker was right that progress would be enhanced if researchers were primed with problems---that way they might be alert to serendipitous solutions. But she was wrong to think that you could assign them problems and "plan" the solution of those problems. Bush was right that the Manhattan Project had succeeded because the basic, hard problems had already been solved. But he was wrong to think that scientists pursuing anything that they were randomly curious about, would be the best way to reach rapid progress.

The "war" analogy may be useful in arguing for a high intensity of effort and funding. But often it is taken further to suggest that the effort to cure a disease should be commanded by a centrally planned hierarchy, based on the common assumption that real war is best fought by hierarchies that centrally plan. (This common assumption has actually been disputed, in different ways, by books such as *Corps Business* (Freedman, 2000), *Start-up Nation* (Senor and Singer, 2011), and *The Generals* (Ricks, 2012).)

Using the war analogy as a guide to medical policy for curing diseases is based on the idea that a centralized hierarchy can predict the right approach, and marshal resources to achieve it, like a conquering army. But a centralized approach will only work when there is clarity on how to solve the problem, and all that remains is to marshal resources to execute the solution. With cancer there have been a variety of approaches with varying degrees of success, including surgical excision, radiation therapy, chemotherapy, angiogenesis, and immunotherapy. Some have predicted that cancer would not be cured by a particular medical technology, but by restricting cancer-causing agents, such as tar in cigarettes, or certain viruses. This has had some success, but many cancers have no known external agents causing them.

One assumption of all of these approaches has been that cancer is one disease that can be cured by the successful pursuit of one common best technology, although there have been major differences on just what that one common best technology is. In contrast, a current approach, one that had not been predicted by the experts from decades past, is that what we call "cancer" may turn out to be several different diseases, with different medical technologies curing different variants.

Those advances against cancer, and other diseases, that have occurred have often been the result of serendipitous events observed by alert medical outsiders (Meyers, 2007; Root-Bernstein and Root-Bernstein, 1997). If the path to breakthrough innovations in medicine is in fact predictable, then centralized policies, such as President Richard Nixon's past declaration of a "war on cancer" or President Barack Obama's current establishment of a "Cancer Moonshot" are plausible (Kolata and Harris, 2016, p. A17). If, on the other hand, breakthrough innovations are not predictable, and depends on alertness to serendipitous events, then it might be wiser to follow the policy attributed to

Mao to 'let a thousand flowers bloom' (Meyers, 2007, p. 173).

6. Conclusions

If we take these steps, how much will we speed up cures for cancer? That is impossible to predict because we do not know what breakthrough innovations, innovative medical entrepreneurs will achieve. We do know, based on past experience, that the pace and number of breakthrough innovations will increase. And we do know that Vincent DeVita, who himself is in a position to know, says that if we allowed practicing physicians to act more entrepreneurially, the immediate effect would be that thousands of those who will otherwise die of cancer in the next year, will live.

Prometheus was punished for bringing fire to humanity. In reality, as in myth, the medical benefactors of humanity often have been punished. They have been ridiculed, defunded, fired, and ignored. If we unbind the entrepreneurs of medical innovation, we will be treating our benefactors more justly, and we will be allowing them to achieve even greater innovations. We may expect that they will respond by bringing us better health and longer lives.

Walt Disney died of cancer at the age of 65. Steve Jobs died of cancer at the age of 56. When the cancer killed their bodies, it also killed their dreams. Cancer is now killing your neighbor, your friend, your co-worker, or your family member. Disney and Jobs had flourished as innovative entrepreneurs because we did not bind innovative dynamism in entertainment or computers. If we had unbound innovative dynamism in medicine, cancer could have been cured in time to save Jobs, and maybe even Disney. If

we unbind innovative dynamism now, it may be in time to save your neighbor, your friend, your co-worker, your family member, or even you.

Footnotes

* The current version is revised from the version presented at the Association of Private Enterprise Education meetings in 2017, and is substantially evolved from an earlier paper presented at the biennial meetings of the International Schumpeter Society in Montreal in 2016. Some paragraphs in the paper overlap with some paragraphs in a section of the concluding chapter of the current draft of my *Innovation Unbound* book. I am grateful for thoughtful comments from two anonymous referees, and the editor Joshua Hall.

¹ DeVita does not specify the gender of the radiologist.

² Some have plausibly argued that increased patient sovereignty will increase breakthrough innovations in medicine (Bhidé, 2017, pp. 23-25; Topol, 2012, 2015).

³ The FDA slows progress in another way, by refusing to approve drugs that slow aging, on the grounds that aging is not a disease, and that the only drugs that should be approved are those that are effective against disease (Anton, 2013; Pontin, 2007, p. 3).

⁴ This is the title of a fascinating book by Gary Klein (2013).

⁵ Gerhard Domagk who discovered one of the first antibiotics, became convinced of the importance of antibiotics through observing infections kill those operated on during WWI. (But the war's contribution to his eventual innovation was more due to the building of motivation than from the building of relevant experiences.) (Hager, 2007, pp. 18-20)

Bibliography

Anton, T. (2013), *The Longevity Seekers: Science, Business, and the Fountain of Youth*.

Chicago: University of Chicago Press.

Ashton, K. (2015), *How to Fly a Horse: The Secret History of Creation, Invention, and Discovery*. New York: Doubleday.

Baumol, W.J. (2005), "Education for innovation: entrepreneurial breakthroughs versus corporate incremental improvements". In Jaffe, A.B., Lerner, J. and Stern, S. (Eds.) *Innovation Policy and the Economy*. Cambridge, Mass.: MIT Press, pp. 33-56.

Bhidé, A. (2017), "Constraining knowledge: traditions and rules that limit medical innovation". *Critical Review* Vol. 29, No. 1, pp. 1-33.

Bucciantini, M., Camerota, M. and Giudice, F. (2015), *Galileo's Telescope: A European Story*. Translated by Bolton, C. Cambridge, MA: Harvard University Press.

Bush, J. and Baker, S. (2014), *Where Does It Hurt?: An Entrepreneur's Guide to Fixing Health Care*. New York: Portfolio.

Cooke, R. (2001), *Dr. Folkman's War: Angiogenesis and the Struggle to Defeat Cancer*. New York: Random House, Inc.

Coss, S. (2016), *The Fever of 1721: The Epidemic That Revolutionized Medicine and American Politics*. New York: Simon & Schuster.

DeVita, V.T. and DeVita-Raeburn, E. (2015), *The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on*

- Cancer Is Winnable--and How We Can Get There*. New York: Sarah Crichton Books.
- Diamond, A.M., Jr. (2012), "The epistemology of entrepreneurship". *Advances in Austrian Economics* Vol. 17, pp. 111-42.
- Fong, K. (2014), *Extreme Medicine: How Exploration Transformed Medicine in the Twentieth Century*, pb reprint ed. New York: The Penguin Press.
- Freedman, D.H. (2000), *Corps Business: The 30 Management Principles of the U.S. Marines*. New York: HarperCollins Publishers, Inc.
- Friedman, D.M. (2007), *The Immortalists: Charles Lindbergh, Dr. Alexis Carrel, and Their Daring Quest to Live Forever*. New York: Ecco.
- Gennawey, S. (2011), *Walt and the Promise of Progress City*. Huntsville, AL: Ayefour Publishing.
- Gilder, G. (1990), *Microcosm: The Quantum Revolution in Economics and Technology*. pb ed. New York: Touchstone.
- Gladwell, M. (2013), *David and Goliath: Underdogs, Misfits, and the Art of Battling Giants*. New York: Little, Brown and Company.
- Hager, T. (2007), *The Demon under the Microscope: From Battlefield Hospitals to Nazi Labs, One Doctor's Heroic Search for the World's First Miracle Drug*. New York: Three Rivers Press.
- Harper, D.A. (1996), *Entrepreneurship and the Market Process: An Enquiry into the Growth of Knowledge*. London: Routledge.
- Isaacson, W. (2011), *Steve Jobs*. New York: Simon & Schuster.
- Jacobs, C.D. (2015), *Jonas Salk: A Life*. New York: Oxford University Press.

- Kahneman, D. (2011), *Thinking, Fast and Slow*. New York: Farrar, Straus and Giroux.
- Klein, G. (2013), *Seeing What Others Don't: The Remarkable Ways We Gain Insights*. Philadelphia, PA: PublicAffairs.
- Kolata, G. and Harris, G. (2016), "'Moonshot' to cure cancer, to be led by Biden, relies on outmoded view of disease". *The New York Times*, 14 January, p. A17.
- Kotler, S. (2014), *The Rise of Superman: Decoding the Science of Ultimate Human Performance*. New York: New Harvest.
- Kounios, J. and Beeman, M. (2015), *The Eureka Factor: Aha Moments, Creative Insight, and the Brain*. New York: Random House.
- Marshall, B.J. (2001), "One Hundred Years of Discovery and Rediscovery of *Helicobacter Pylori* and Its Association with Peptic Ulcer Disease", in Mobley, H.L.T., Mendz, G.L. and Hazell, S.L. (Eds.) *Helicobacter Pylori: Physiology and Genetics*. Washington, D.C.: ASM Press, pp. 19-24.
- Meyers, M.A. (2007), *Happy Accidents: Serendipity in Modern Medical Breakthroughs*. New York: Arcade Publishing.
- Miller, G.W. (2000), *King of Hearts: The True Story of the Maverick Who Pioneered Open Heart Surgery*. New York: Crown.
- Mukherjee, S. (2010), *The Emperor of All Maladies: A Biography of Cancer*. New York: Scribner.
- Pontin, J. (2007), "Slipstream; an age-defying quest (red wine included)". *The New York Times*, 8 July, p. 3.
- Ricks, T.E. (2012), *The Generals: American Military Command from World War II to Today*. New York: Penguin Press.

- Root-Bernstein, R.S. and Root-Bernstein, M.M. (1997), *Honey, Mud, Maggots, and Other Medical Marvels: The Science Behind Folk Remedies and Old Wives' Tales*. Boston, MA: Houghton Mifflin.
- Rosen, W. (2010), *The Most Powerful Idea in the World: A Story of Steam, Industry, and Invention*. New York: Random House.
- Rosenberg, S.A. and Barr, J.M. (1992), *The Transformed Cell: Unlocking the Mysteries of Cancer*. New York: G.P. Putnam's Sons.
- Schumpeter, J.A. (1950), *Capitalism, Socialism and Democracy*. 3rd ed. New York: Harper and Row, (first edition was 1942).
- Senor, D. and Singer, S. (2011), *Start-up Nation: The Story of Israel's Economic Miracle*. revised pb edition ed. New York: Twelve.
- Shreeve, J. (2004), *The Genome War: How Craig Venter Tried to Capture the Code of Life and Save the World*. New York: Alfred A. Knopf.
- Smith, G.C.S. and Pell, J.P. (2003), "Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials". *BMJ* Vol. 327, No. 7429, pp. 1459-61.
- Snyder, L.J. (2015), *Eye of the Beholder: Johannes Vermeer, Antoni Van Leeuwenhoek, and the Reinvention of Seeing*. New York: W. W. Norton & Company, Inc.
- Sunstein, C.R. (2005), *Laws of Fear: Beyond the Precautionary Principle*. hb ed, *The Seeley Lectures*. Cambridge, UK: Cambridge University Press.
- Thiel, P. and Masters, B. (2014), *Zero to One: Notes on Startups, or How to Build the Future*. New York: Crown Business.

- Thierer, A. (2016), *Permissionless Innovation: The Continuing Case for Comprehensive Technological Freedom*. pb, revised and expanded ed. Arlington, VA: Mercatus Center at George Mason University.
- Topol, E. (2012), *The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care*. New York: Basic Books.
- Topol, E. (2015), *The Patient Will See You Now: The Future of Medicine Is in Your Hands*. New York: Basic Books.
- Venter, J.C. (2007), *A Life Decoded: My Genome: My Life*. New York: Viking Adult.
- Wagner, A. (2014), *Arrival of the Fittest: Solving Evolution's Greatest Puzzle*. New York: Current.
- Wang, J., Veugelers, R. and Stephan, P. (2017), "Bias against novelty in science: a cautionary tale for users of bibliometric indicators". *Research Policy* Vol. 46, No. 8, pp. 1416-36.
- Westfall, R.S. (1985), "Science and patronage: Galileo and the telescope". *ISIS: Journal of the History of Science in Society* Vol. 76, No. 1, pp. 11-30.
- Wilkinson, A. (2015), *The Creator's Code: The Six Essential Skills of Extraordinary Entrepreneurs*. New York: Simon & Schuster.